Newsroom
Strive to Deliver Breakthroughs
-
May 06, 2019
Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics
Global collaboration focused on new antibody treatments in the fields of oncology and immunology. Cambridge, MA, Rotterdam, NL, Shanghai, CN &n...
View more -
January 22, 2019
Harbour BioMed integrates the Beacon® Platform to Accelerate Antibody Discovery
Harbour BioMed will be the first company in Greater China to equip and leverage the use of this pioneering technology Emeryville, Calif...
View more -
January 04, 2019
Company also promotes Xiaoxiang Chen, MD to Chief Development Officer, and Mai-Jing Liao, Ph.D., MBA to Chief Business Officer
CAMBRIDGE, Mass ，SHANGHAI，China & ROTTERDAM, The Netherlands . January 4, 2019– Harbour BioMed announced the appointment of Atul De...
View more -
January 04, 2019
Harbour BioMed Appoints Atul Deshpande, Ph.D. MBA, Chief Strategy Officer and Head of U.S. Operations
CAMBRIDGE, Mass ，SHANGHAI，China & ROTTERDAM, The Netherlands . January 4, 2019– Harbour BioMed announced the appointment of Atul De...
View more -
September 21, 2018
Harbour BioMed Receives Approval to Start the Phase II Clinical Trial of Its Innovative Drug Candidate for The Treatment of Inflammatory Eye Disease
——The first global innovative biologic in development for the treatment of dry eye disease in China ——The approval for the clinical ...
View more -
August 27, 2018
Harbour BioMed Raises $85 Million in Series B Financing to Accelerate Its Innovative Pipeline
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. – Harbour BioMed announced today that it has completed a Series B round financing o...
View more -
August 20, 2018
Harbour BioMed Announces Global Strategic Partnership with Kelun-Biotech to Develop and Commercialize A167, An Anti-PD-L1 Antibody, for Treatment of Cancer
· Harbour BioMed to develop and commercialize A167 worldwide (excluding Greater China); companies to collaborate on A167 combination therapie...
View more -
August 07, 2018
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
- Exclusive license agreement potentially worth more than $120 million in addition to royalties - GBR 1302 is a clinical stage, HER2xCD3 bispecifi...
View more -
June 25, 2018
WuXi Biologics and Harbour BioMed Announce Strategic Development and Manufacturing Partnership
– WuXi Biologics’ first collaborative project based on novel fully human antibody platform – HCAb (“heavy chain only” antibodies)...
View more -
June 11, 2018
LakePharma and Harbour Antibodies Announce Partnership for H2L2 Transgenic Mouse Platform for Therapeutic Antibody Discovery
Agreement Provides for Easy Access to H2L2 Platform Use with LakePharma’s Discovery and Development Services BELMONT, Calif. and CAMBRIDGE, ...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1